Caffeine intake as a protective factor in the development and progression of Parkinson's disease and Alzheimer's disease: an integrative review

• Autor(a) principal: Paiva, Tatiana Lima
• Data de Publicação: 2022
• Outros Autores: Santos, Giovanni Ferreira, Coutinho, João Otávio Bayão, Mendonça, Mariana Moreira Munhoz, Dutra, Dalbert Samuel, Leite, Jorge Antonio de Moura, Rigueira, José Marcos Leite, Mazzieiro, Giulia Pieroli, Ferreira, Louvana Cristelle Camargos, Araújo, Bethânia Cristhine de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/31424
• topic: Cafeína; Enfermedad de Alzheimer; Enfermedad de Parkinson; Neuroprotección; Neurodegeneración.; Cafeína; Doença de Alzheimer; Doença de Parkinson; Neuroproteção; Neurodegeneração.; Caffeine; Alzheimer's Disease; Parkinson's Disease; Neuroprotection; Neurodegeneration.

Introduction: The prevalence of Alzheimer's disease (AD) and Parkinson's disease (PD) tends to increase with the aging population. Currently, the therapeutic schemes for these diseases cannot achieve a cure and are also not frequently updated, which highlights the need for other options to improve the quality of life of these patients. Given that these dementia syndromes have a multifactorial etiology, diet, through coffee, has shown significant evidence in neuronal degeneration, which is one of the main aspects altered in the development of these pathologies. Methodology: This is an integrative review, which sought to answer what the possible effects of caffeine as a protective factor in the development and progression of AD and PD, in the databases: Virtual Health Library (VHL) National Library of Medicine (PubMed MEDLINE) and Scientific Electronic Library Online (Scielo). Results and Discussion: Caffeine acts in the central nervous system (CNS) by mimicking the adenosine receptors, more concentrated in the A1R and A2aR receptors. As a competitive antagonist, caffeine could possibly reduce the processes of b-amyloid plaque formation in AD and reduce neuroinflammation and neurodegeneration in PD, besides other possible mechanisms. Conclusion: The delimitation of a consensus on the dose/effect relation resulting from the use of caffeine is difficult to establish and a consensus is not yet observed; however, it is possible to observe that an intake between 200mg to 511mg per day could bring beneficial effects both in PD and in AD, overcoming the possible side effects.